Total Funding
12
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
871673
Durata Therapeutics is a clinical, development-stage pharmaceutical company focused on the treatment of infectious diseases.
Allison Wey: Vice President, Investor Relations & Public AffairsPast Role: Par Pharmaceuticals, Vice President, Investor Relations and Corporate Affairs
Richard U. De Schutter: Independent Director, Chairman of the BoardPast Role: Monsanto, Vice Chairman and Chief Administrative Officer
About the Company
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.
Durata is focused on Vicuron’s antibiotic
drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.
